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Unraveling the mechanism of action and molecular target of small molecules remains a major
challenge in drug discovery. While many cancer drugs target genetic vulnerabilities, loss-of-
function screens fail to identify essential genes in drug mechanism of action. Here, we report
CRISPRres, a CRISPR-Cas-based genetic screening approach to rapidly derive and identify
drug resistance mutations in essential genes. It exploits the local genetic variation created by
CRISPR-Cas-induced non-homologous end-joining (NHEJ) repair to generate a wide variety
of functional in-frame mutations. Using large sgRNA tiling libraries and known drug–target
pairs, we validate it as a target identiﬁcation approach. We apply CRISPRres to the anticancer
agent KPT-9274 and identify nicotinamide phosphoribosyltransferase (NAMPT) as its main
target. These results present a powerful and simple genetic approach to create many protein
variants that, in combination with positive selection, can be applied to reveal the cellular
target of small-molecule inhibitors.
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Identifying the cellular target of a chemical hit with valuablebioactivity is a crucial step in drug discovery and develop-ment1. However, unraveling the molecular target of a small-
molecule drug still remains a challenging, laborious, and complex
process. Although many target deconvolution methods2, 3, such
as chemical proteomics, have successfully been applied, they often
reveal more than one plausible candidate target protein and carry
the risk of identifying interactions that are not related to the
compound’s activity. The gold standard proof for a drug’s target
is the identiﬁcation of functional mutations that confer resistance
in a cellular context. For this reason, genetic screens in particular,
are very powerful tools for drug mechanism of action studies4.
However, current screens either are not well suited to identify
essential genes or require whole-exome sequencing combined
with complex bio-informatics to deconvolute the relevant drug
resistance conferring mutations. For example, loss-of-function
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approaches have been applied to obtain drug resistance5–8, but
innately lack the ability to comprehensively detect gain-of-
function mutations and fail to nominate essential proteins
involved in drug mechanism of action. Classical step-wise drug
resistance selection enables selection of gain-of-function muta-
tions but is laborious9 and often results in off-target multi-drug
resistance10. Recently, chemical mutagenesis to increase the
occurrence of single-nucleotide variants has been described11.
However, until now, this chemical mutagenesis approach has only
been applied to identify loss-of-function resistance mutations to
the prototype acute myeloid leukemia drug 6-thioguanine. It
remains to be investigated whether this approach can also detect
gain-of-function resistance mutations. Another bottleneck of
these general random mutagenesis approaches is the discovery of
the resistance mutations. They require sequencing of the large
human exome in individual clones11–14 while the genomic het-
erogeneity of the cell line makes the deconvolution of the relevant
resistance-conferring mutations especially challenging. As such,
the ﬁeld would greatly beneﬁt from an approach that can accel-
erate the drug resistance selection process and simplify sub-
sequent identiﬁcation of the relevant drug resistance mutations.
Moreover, because many cancer drugs target essential proteins,
there is a strong need for a method that can easily generate and
identify drug resistance mutations in essential genes.
Drawing a parallel to the use of UV-mediated double-strand
breaks (DSBs) to enhance mutagenesis15, we reasoned that
introduction of DSBs by targeted endonucleases, such as SpCas9,
and the subsequent error-prone repair via non-homologous end-
joining (NHEJ) may be exploited for rational protein mutagenesis
to facilitate drug resistance selection. Here, we describe a
CRISPR-based method, entitled CRISPR-induced resistance in
essential genes (CRISPRres), to rapidly acquire and identify
functional drug resistance mutations. We show that large-scale
CRISPR single-guide RNA (sgRNA) gene tiling libraries can be
applied as a genetic screening approach in cancer cells to identify
the molecular target of a chemical inhibitor. Finally, we also
demonstrate that the methodology is compatible with the class 2
type V AsCpf1 CRISPR system, increasing the resolution of the
method.
Results
Rapid generation of drug-resistant variants with CRISPR-
Cas9. To develop the method, we ﬁrst designed sgRNAs targeting
known resistance hotspots in genes sensitive to three cancer
drugs: KPT-185, a preclinical analog of the XPO1 inhibitor seli-
nexor16–19, ispinesib, an antineoplastic kinesin-5 (KIF11)
inhibitor13, 20, and triptolide, an antiproliferative agent targeting
ERCC314, 21 (Fig. 1a, b). The respective sgRNAs were tran-
siently expressed together with SpCas9 in chronic myeloid
leukemia-derived HAP1 cells which were then treated with four
different concentrations of the corresponding drug. Within a few
days of treatment, colonies that were resistant to the drugs
appeared on the culture plates (Fig. 1c, d). Next-generation
sequencing of the targeted hotspot loci of these resistant colonies
revealed known as well as many novel resistant protein variants
(Fig. 1e and Supplementary Figs. 1a, 2, and 3). Mutations were
mainly localized within 17 bp upstream of the SpCas9 cleavage
site on the non-target strand and consisted of insertions, dele-
tions, and missense mutations (Fig. 1f, g). The majority of the
sequences consisted of in-frame mutations, but some frameshift
and nonsense mutations were also detected. Because the targeted
genes are essential for survival, this suggests that some of the cells
had turned diploid during the experiment, a phenomenon known
to occur spontaneously in HAP1 cells22. For XPO1, more than 40
different in-frame variants containing a mutation or deletion of
the C528 residue were detected (Fig. 1e left panel and Supple-
mentary Fig. 1a). This is in agreement with the fact that this
single cysteine residue is absolutely essential for KPT-185/seli-
nexor activity16–18. However, until now, only a single serine
substitution had been reported to confer cancer cells with resis-
tance to these drugs16. As we were surprised to see that an
essential protein such as XPO1 can accommodate such a wide
variety of diverse mutations in a functional domain, we derived
different single-cell clones from the original compound selected
cell pools to conﬁrm the resistance-conferring mutations by
Sanger sequencing and cell viability in the presence of the drug
(Supplementary Fig. 1b, c). For KIF11, the majority of the
sequencing reads contained a 9 bp deletion from codon D130 to
L132 (Fig. 1e middle panel and Supplementary Fig. 2). Interest-
ingly, the majority of sequences shared a deletion or mutation of
L132, which appears to be sufﬁcient for drug resistance per se.
Mutation of residue A133, known to confer ispinesib resistance13,
was not readily detected, which might be explained by the fact
that the codon for A133 is at the 3′ end of the SpCas9 cut site.
Indeed, mutations were mainly observed upstream of the SpCas9
cut site, away from the NGG protospacer adjacent motif (PAM)
(Fig. 1g middle panel). Interestingly, in contrast to the selinexor
resistance mutations, almost all ispinesib-resistant sequence
alterations were deletions. For ERCC3, we mainly identiﬁed in-
frame insertions and some deletions between codons K165 and
K167 (Fig. 1e right panel and Supplementary Fig. 3). We also
targeted an additional resistance hotspot at ERCC3 codon D54,
which resulted in in-frame deletions of 1–8 amino acids
Fig. 1 Spontaneous genetic variation generated by CRISPR-Cas9-induced NHEJ repair facilitates rapid selection of drug resistant protein variants.
a Representation of sgRNAs targeting resistance hotspots for KPT-185/selinexor (XPO1 codon C528), ispinesib (KIF11 codons D130 and A133), and
triptolide (ERCC3 codons S162 and Y163). The SpCas9 cleavage site is indicated (red arrowhead) and residues conferring drug resistance when altered are
hightlighted in blue. b Chemical structures of the antineoplastic agents. c SpCas9-induced NHEJ repair at resistance hotspots facilitates rapid selection of
resistant colonies. Cells were transfected with SpCas9 plasmid (top) or co-transfected with SpCas9 and sgRNA expressing plasmids (bottom). KPT-185
(300 nM), ispinesib (4 nM), or triptolide (10 nM) were added 48 h after transfection and selection was maintained for 7–10 days before visualization. The
experiment was performed with four different compound concentrations (KPT-185: 0.3, 0.6, 1.5, 2 μM; ispinesib: 4, 8, 20, 40 nM; triptolide: 2, 4, 10, 20
nM) and replicated at least once (see Supplementary Figs. 1, 2, and 3), but only one representative concentration is shown. d Cell viability assays of wild-
type (parental) and the different resistant cell populations obtained after selection of mutagenized cells with four different concentrations of compound.
Data points are normalized relative to untreated cells and represent mean± s.d. obtained from three experiments performed in triplicate. e Amino-acid
sequence variants, determined by targeted amplicon sequencing analysis with CrispRVariants present in the resistant cell pools described in c. The wild-
type sequence is shown for reference and resistance hotspot residues are highlighted in blue. The SpCas9 cleavage site is indicated (red arrowhead). For a
complete list of amino-acid variants from all resistant cell pools and replicates see Supplementary Figs. 1a, 2, 3. f The relative abundance of all alleles with a
read frequency ≥0.5% is shown and categorized per sample into four different mutation types. The values represent averages of two (XPO1, ERCC3) or
three (KIF11) experiments for each concentration of the compound. g Single-nucleotide variant occurrence at the sgRNA target sites observed across all
mutagenized and selected cell pools from c. The red arrowhead indicates the Cas9 cut site. The values represent averages of eight (XPO1, ERCC3) or 12
(KIF11) experiments
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consistent with previous observations14 (Supplementary Fig. 4).
To conﬁrm that drug resistance was obtained by targeted
CRISPR-Cas9-mediated mutagenesis and not by multi-drug
resistance, the drug-resistant colonies were treated with all three
drugs and no cross-resistance between the three different drug-
resistant cell pools was observed (Supplementary Fig. 5). To
demonstrate that this mutagenesis methodology can be broadly
applied to other cell types, similar results were obtained in the
pseudodiploid acute pro-myelocytic leukemia HL-60 and colon
cancer HCT 116 cell lines (Supplementary Figs 6 and 7).
To validate the observed drug resistance mutations,
we reinstalled one protein variant for each drug
(XPO1C528S,E529V,Q530H,K531I; KIF11L132Δ; ERCC3V166_K167insL)
into its native locus in parental cells using CRISPR-Cas9-
mediated homology-directed repair (HDR) of a ssDNA donor
template (Supplementary Fig. 8a). Silent mutations not identiﬁed
in our original selection were included to control for HDR
(Supplementary Fig. 8b). All three donor templates provided
strong protection against respective drug treatment (Supplemen-
tary Fig. 8a, c), validating the results obtained by the targeted
b
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CRISPR-Cas9-induced NHEJ-based mutagenesis. We also
assessed protein function of the resistant variants and how this
is affected by the respective drugs. We ﬁrst visualized the XPO1-
dependent nuclear export of a GFP protein fused to the nuclear
localization signal (NLS) of SV40 and the nuclear export signal
(NES) from the prototype XPO1 cargo protein kinase inhibitor
(PKI). This fusion protein actively shuttles between the nucleus
and cytoplasm but localizes in a XPO1-dependent manner to the
cytoplasm in steady state (Supplementary Fig. 8d panel a)18.
CRISPR-Cas9-mediated knockout of XPO1 in both wild-type and
mutant cells resulted in nuclear accumulation of the reporter
protein, demonstrating functionality of the resistant XPO1
protein variant (Supplementary Fig. 8d panel b). Upon inhibition
of the XPO1-mediated nuclear export by selinexor, the GFP
fusion protein accumulated in the nucleus of wild-type cells,
while in XPO1C528S,E529V,Q530H,K531I mutant cells its localization
remained unaffected (Supplementary Fig. 8d panel c), again
demonstrating that the mutation confers resistance to inhibition
of XPO1 function by selinexor. As an additional conﬁrmation of
drug resistance, we further demonstrated that the resistance
mutations prevent the drug from binding directly to XPO1 by the
absence of pull-down of mutant XPO1 protein with a biotinylated
analog of selinexor (Supplementary Fig. 8e). For the KIF11L132Δ
resistance mutation, the formation of mitotic spindles in genome-
edited KIF11L132Δ cells was similar to that in the wild-type cells
(Supplementary Fig. 8f panel a). Knockout of KIF11 disrupted
bipolar spindle formation in both wild-type and KIF11L132Δ
mutant cells (Supplementary Fig. 8f panel b), demonstrating that
the mutant protein is functional. Furthermore, the KIF11L132Δ
mutation protected cells from monopolar mitotic spindle
formation induced by ispinesib treatment (Supplementary Fig. 8f
panel c).
Taken together, these results demonstrate that the spontaneous
genetic variation generated during NHEJ repair at the locus of
CRISPR-SpCas9-mediated DSBs can be exploited to signiﬁcantly
accelerate the selection of functional drug resistance mutations; a
ﬁnding independently conﬁrmed by Ipsaro et al.23 and Donovan
et al.24.
Target identiﬁcation by sgRNA tiling of multiple genes. To
further investigate whether this approach can be applied as a
genetic screen to directly identify the molecular target of a che-
mical inhibitor, we designed a lentiviral tiling sgRNA library
spanning all possible NGG PAM sites in the coding sequence
from nine different genes (2,209 sgRNAs), including kinesin-5
(KIF11) (Supplementary Data 1). HAP1 cells stably expressing
SpCas9 were transduced with this lentiviral sgRNA library and
subsequently treated with ispinesib for a period of 14 days
(Supplementary Fig. 9a). Drug-resistant colonies formed rapidly
and were resistant to ispinesib (Supplementary Fig. 9b). Four
sgRNAs, which all targeted KIF11, were highly enriched in the
pool of resistant clones (Supplementary Fig. 9c and d, and Sup-
plementary Data 2). When transfected separately, these sgRNAs
were able to confer HAP1 cells with ispinesib resistance, with the
sgRNAs targeting codon A133 being the most efﬁcient (Supple-
mentary Fig. 9e). The underlying resistance mutations at the
genomic locus targeted by this sgRNA consisted of multiple in-
frame variations around the KIF11 A133 codon (Supplementary
Fig. 9f), consistent with previous results (Fig. 1e middle panel),
and map to the ispinesib-binding site. These results show that
CRISPR-Cas9 mutagenesis scanning on a pool of genes can be
used to ﬁsh out both the target protein and the molecular
interaction site of a small-molecule inhibitor.
To extend the use of this approach to drugs for which
resistance has not yet been developed or for which the target is
not known, we designed two complementary lentiviral sgRNA
tiling libraries containing the target genes of FDA approved (115
genes, divided in two subpools A and B of ±20,000 sgRNAs each)
or investigational antineoplastic drugs (75 genes, divided in two
subpools C and D containing ±12,000 sgRNAs each) (Supple-
mentary Data 3 and 4). As validation of these libraries, we applied
sublibrary B to SpCas9+ HAP1 cells to obtain resistance against
the proteasome inhibitor bortezomib, which targets proteasome
subunit beta type-5 (PSMB5) (Fig. 2a). Surviving colonies were
harvested within 19 days after treatment. These were resistant to
bortezomib treatment (Fig. 2b) and documentation of the
sgRNAs present in the resistant cell population revealed four
sgRNAs targeting known PSMB5 resistance hotspots amongst
other sgRNAs (Fig. 2c, d, Supplementary Data 5). Validation of
the >100-fold enriched sgRNAs revealed that PSMB5 was the sole
gene that, when mutagenized, conferred bortezomib resistance
(Fig. 2e, f). Deep sequencing of the genomic region targeted by
these sgRNAs identiﬁed multiple in-frame mutations in PSMB5
(Fig. 2f). Most of these mutations are similar to known drug
resistance mutations and map to the bortezomib binding
site25, 26. More speciﬁcally, the most enriched mutation
(A108T) alters a residue known to bind bortezomib directly.
Other well-known bortezomib drug resistance mutations (C111F
and M104I) were identiﬁed, as well as new and earlier described
mutations around threonine 80 (S77A, A79G, T80A, T80del),
which is also implicated in the binding of bortezomib. One
peculiar intronic mutation (deletion of the nucleotides 5′-
GCCCCCTT) was identiﬁed 11 bp downstream of the
exon1–intron1 boundary. Although we could not validate the
associated sgRNA (PSMB5_117) (Fig. 2e), another recent study
Fig. 2 Validation of CRISPR-Cas-mediated mutagenesis scanning as a target identiﬁcation approach using large sgRNA tiling libraries. a Overview of the
workﬂow for the CRISPR-Cas9-based target identiﬁcation screen used for bortezomib. Two lentiviral sgRNA sublibraries, together tiling 115 genes targeted
by FDA-approved anticancer drugs, were constructed (A: ABL1 through HDAC9; B: IFNAR1 through VEGFB). Sublibrary B was transduced into HAP1 cells
stably expressing SpCas9, enriched with puromycin and treated with 30 nM bortezomib for 19 days. sgRNAs in the surviving cells were then sequenced
and validated. b Cell viability of parental and the pool of bortezomib-resistant HAP1 cells in the presence of different concentrations of bortezomib. Data
points represent mean± s.d. obtained from three experiments performed in triplicate. c Representation of the different sgRNAs in cells before (after
puromycin selection) and after treatment with 30 nM bortezomib as determined by EdgeR analysis of next-generation sequencing data. Each dot
represents a different sgRNA. A value of 1 was added to each read count to facilitate log transformation. d Overview of the sgRNA hits enriched in the
bortezomib-surviving cells. e Validation of the individual sgRNA hits by assessing their ability to induce bortezomib resistance. Individual sgRNAs were
cloned into an expression vector and transfected separately into SpCas9+ HAP1 cells. Cells were treated with 20 nM bortezomib for 8 days and then
counted using trypan blue exclusion. An sgRNA targeting the AAVS1 safe harbor locus was used as negative control. The columns represent mean± s.d.
obtained from two separate experiments. f PSMB5 amino-acid variants present in the pool of bortezomib-resistant cells as determined by CrispRVariants
analysis of next-generation targeted amplicon sequencing. g PSMB5 chymotrypsin-like activity as measured in parental HAP1 and a single-cell-derived
PSMB5A108T mutant obtained from the pool of bortezomib-resistant cells. Cells were untreated or treated for 2 h with 12.5 nM bortezomib. Values
represent mean± s.d. obtained from a single experiment performed in triplicate; *p-value< 0.05 *, ****p-value< 0.0001 (two-way ANOVA with Bonferroni
correction for multiple testing), ns not signiﬁcant, RLU relative light unit
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using targeted mutagenesis of PSMB5 also identiﬁed an intronic
point mutation in the ﬁrst intron of PSMB5 in bortezomib-
resistant cells25. To further investigate the effect of bortezomib on
mutated cells, we obtained a single-cell-derived A108T mutant
from the pool of resistant cells and examined chymotrypsin-like
proteasome activity in these cells (Fig. 2g). Baseline proteasome
activity in mutant cells was decreased when compared to the
wild-type (p< 0.0001) but treatment with bortezomib did not
inhibit proteasome activity, while it was severely impaired in the
parental wild-type (p< 0.0001).
These results clearly validate this tiling library and demonstrate
the feasibility of a SpCas9-directed mutagenesis scanning strategy
for target deconvolution on a larger scale.
Identiﬁcation of the cellular target of KPT-9274. Next, we
applied the approach to the clinical stage anticancer compound
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KPT-9274, an orally bioavailable small molecule with potent
activity against different cancer types. Based on chemical pro-
teomics experiments, KPT-9274 has been suggested to interact
with the p21-associated kinase 4 (PAK4)27 and inhibition of
NAD+ biosynthesis has also been reported28. However, the causal
association between these activities and cancer cell sensitivity to
KPT-9274 remains to be investigated. Therefore, we applied our
sgRNA tiling library containing 75 target genes of investigational
antineoplastic drugs to HAP1 and chronic myelogenous leukemia
K-562 cells stably expressing SpCas9 (Fig. 3a and Supplementary
Data 4). Cells were pulsed three times with KPT-9274 (Fig. 3b)
and colonies that were resistant to KPT-9274 (Fig. 3c) appeared
within 7–14 days post treatment. In both cell lines, six sgRNAs,
all targeting nicotinamide phosphoribosyl transferase (NAMPT),
were enriched in the resistant cell pools (Fig. 3d, e, and Supple-
mentary Data 6). From these, ﬁve were identical in both cell lines
(Fig. 3f). One sgRNA, targeting NAMPT codon G383, was by far
the most enriched in both HAP1- and K-562-resistant cell pools
and represented between 22% and 38% of total sgRNAs. In
addition, an sgRNA targeting NAMPT that was present as little as
0.02% could also be detected. All enriched sgRNAs could be
conﬁrmed to confer resistance when transfected separately
(Fig. 3g). The same KPT-9274 resistance could also be elicited in
pancreas carcinoma MIA PaCa2 and multiple myeloma OPM-2
cells by co-transfection of the NAMPT sgRNAs with SpCas9
(Supplementary Fig. 10a). The original KPT-9274-resistant cell
pools were also cross-resistant to the NAMPT inhibitor FK86629
(Supplementary Fig. 10b, c), and the same NAMPT sgRNAs
identiﬁed in the screen were able to confer HAP1 cells with
resistance to FK866 (Supplementary Fig. 10d). Moreover, addi-
tion of β-nicotinamide mononucleotide, the product of the
enzymatic reaction catalyzed by NAMPT, to parental wild-type
cells provided similar protection against KPT-9274-induced
cytotoxicity as the NAMPT sgRNAs from the screen (compare
Fig. 3c with Supplementary Fig. 10e), further pinpointing
NAMPT as a key cellular target of KPT-9274.
Next, we identiﬁed the underlying resistance mutations present
in the mutagenized population of cells obtained from the sgRNA
scanning screen. As some of the enriched sgRNAs had over-
lapping target sequences (NAMPT_34 and NAMPT_33;
NAMPT_137 and NAMPT_145), only four domains within the
NAMPT protein were effectively targeted. Deep sequencing of
NAMPT at these four domains revealed a variety of mutations
(Fig. 3h and Supplementary Data 7). The G383del mutation was
by far the most prevalent, ranging from 10 to 52%, and was the
only mutation identiﬁed throughout all samples. The
P236_V237del mutation was present only in the two replicates
from the HAP1 experiment, while the G381_G384del mutation
was only present in the K-562 replicates. Sequencing of the ﬁrst
NAMPT exon, which is targeted by the NAMPT_145 and
NAMPT_146 sgRNAs, proved to be difﬁcult due to the high GC
content in the ﬂanking introns. However, in some samples we did
manage to identify I11_K19del, S17del, and Y18del mutations,
although we could not quantify these mutations. Other in-frame
mutations, including P238_Y240insAAEHS, S275T,
S382_G385del, and some frameshift mutations, were identiﬁed
in individual replicates. Frameshift mutations are most probably
present in hemizygous cells since knockout of NAMPT is lethal in
HAP1 and K-562 cells (Supplementary Fig. 11d). We also
identiﬁed some low prevalent NAMPT mutations that did not
localize to the target sites of the enriched sgRNAs. Three of these
mutations (G217E, G217V, G217R) alter the G217 residue that
has been identiﬁed earlier to confer resistance to NAMPT
inhibitors30. These mutations were found in one of the two
replicates and were likely already present in the heterogenous
parental population or arised during the experiment. Finally, one
known SNP (S301S; rs2302559 (dbSNP)) was also detected in
both replicate HAP1 screens.
We further validated the G383del mutation, which was the
only mutation detected in both HAP1 and K-562 replicates, by
reinstalling it into its native locus by CRISPR-induced HDR of
parental HAP1 cells (Supplementary Fig. 11a). HDR-edited cells
were resistant to KPT-9274 treatment and were also cross-
resistant to FK866 (Supplementary Fig. 11b, c), again providing
further evidence for NAMPT as the key cellular target of KPT-
9274. To examine the function of NAMPT protein containing the
G383del mutation, cellular NAD+ levels were measured in
absence and presence of KPT-9274. Baseline NAD+ levels were
slightly elevated in mutant cells (Fig. 3i left panel), and treatment
of parental cells with KPT-9274 decreased NAD+ levels rapidly,
while the G383del mutation conferred resistance (Fig. 3i right
panel).
Next, to unambiguously validate our results and corroborate
the validity of the conclusions taken from the mutagenesis
scanning approach, we crystallized a NAMPT dimer in complex
with KPT-9274 (Fig. 4a and Supplementary Fig. 12) (PDB: 5NSD)
and explained the identiﬁed resistance mutations by modeling
(Fig. 4b). Crystallographic analysis of the binding mode revealed
that two KPT-9274 molecules are bound to the NAMPT dimer
(Fig. 4a). The binding mode is largely similar to that of FK866
(Fig. 4b left lower panel)29. In more detail, the amino-pyridinyl of
KPT-9274 is coordinated via pi-stacking interactions between
tyrosine 18 and phenylalanine 193. Furthermore, the amide linker
is well coordinated via hydrogen-bonding interactions and the
Fig. 3 Identiﬁcation of NAMPT as the cellular target of KPT-9274 using a CRISPR-Cas9 tiling library. a Experimental workﬂow for the CRISPR-Cas9-based
target identiﬁcation screen for KPT-9274. HAP1 or K-562 SpCas9+ cells were transduced with the investigational target gene library spanning 75 genes,
enriched by puromycin selection and treated with KPT-9274. Surviving cells were then harvested and the sgRNAs were sequenced. The experiment was
performed in duplicate for both cell lines. b Chemical structure of KPT-9274. c Resistance proﬁle of parental cells and transduced cell populations that
survived treatment with KPT-9274. Cell viability was measured in the presence of increasing concentrations of KPT-9274 and was adjusted to the
untreated control. Data points represent mean± s.d. obtained from two (HAP1) or ﬁve (K-562) experiments performed in triplicate. d Enrichment scores of
the sgRNAs present in transduced HAP1 cells after treatment with KPT-9274 (300 nM). Fold change was determined for each sgRNA by taking the log2 of
the reads per million (RPM) after treatment added by 1 (adjusted) divided by the adjusted RPM before treatment. Read counts were determined using
EdgeR and each dot represents an sgRNA. e Enrichment scores of the sgRNAs present in transduced K-562 cells after treatment with KPT-9274. f
Overview of the enriched sgRNAs present in the transduced cells after treatment with KPT-9274. Values represent averages of the replicate experiments
for each cell line. FC: adjusted fold change. g sgRNAs identiﬁed in the screen were validated by assessing their ability to induce drug resistance. Each
sgRNA was transfected separately and cells were treated with KPT-9274 for four (HAP1) or six (K-562) days. Surviving cells were counted using trypan
blue exclusion. A safe-targeting sgRNA (AAVS1) was included as negative control. The columns indicate mean± s.d. obtained from two experiments. h
Overview of NAMPT mutations detected in KPT-9274-resistant cells from HAP1 replicate #1 (see also Supplementary Data 7). i NAD+ levels in parental
and HDR-edited NAMPTG383del HAP1 cells treated with increasing concentrations of KPT-9274. The left panel shows the untreated baseline NAD+ levels.
Two experiments were performed in duplicate and values represent mean± s.d. *p-value< 0.05 two-tailed Mann–Whitney U test
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02349-8 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:502 |DOI: 10.1038/s41467-017-02349-8 |www.nature.com/naturecommunications 7
free electron pairs of the amide oxygen are stabilized by a
hydrogen bond originating from serine 275. The nitrogen forms a
hydrogen bond with a water molecule that further interacts with
the carboxyl group of aspartate 219 and the hydroxyl group of
serine 241. At the solvent exposed regions of the binding site, the
chemical composition of KPT-9274 and the interactions with the
NAMPT protein are different from FK866. The KPT-9274 core
consists of a rigid benzofuran moiety, contrary to the ﬂexible
carbon chain linker in FK866 (compare Fig. 3b and Supplemen-
tary Fig. 10b). KPT-9274 is branched and binds to two different
solvent exposed patches whereas FK866 only occupies a single
hydrophobic site. The ﬁrst hydrophobic patch outlined by the
hydrophobic sidechains of isoleucine 309, isoleucine 351, and
alanine 379 is occupied by the aromatic ﬂuorophenyl group of
KPT-9274. The second solvent exposed binding site, which is
only covered by KPT-9274, consists of tyrosine 188 and tyrosine
240 that interact with the diﬂuoro-1-piperidinyl carbonyl phenyl
group via Van der Waals interactions and a hydrogen bond
between the carbonyl group and the amino group of lysine 216.
Importantly, the sgRNAs identiﬁed from our screen are targeting
close to residues (tyrosine 18, tyrosine 240, serine 241, serine 275,
and alanine 379) that are conﬁrmed by this co-crystal to take part
in the binding mode of the drug, demonstrating the power of the
CRISPR-Cas9-induced mutagenesis scanning approach.
To investigate the inﬂuence of the mutations on the NAMPT
structure and KPT-9274 binding, the G383del and the
P236_V237del mutations were modeled utilizing MOE (The
Chemical Computing Group, Montreal, Canada) implemented
with the Amber99 forceﬁeld31 (Fig. 4b right panels). Deletion of
G383 causes a conformational change of the G383–385 stretch,
which destablizes the conformation of F193 and thereby prevents
pi-stacking with the ligand. Both P236_V237del and
P238_Y240insAAEHS mutants cause a displacement of the loop
containing the Y240 residue resulting in steric incompatibility with
the KPT-9274 4,4-diﬂuoro-1-piperidinylcarbonylphenyl group.
Altogether, these ﬁndings clearly pinpoint NAMPT as the
primary target of KPT-9274 and illustrate the importance of
target veriﬁcation by discovery of drug resistance mutations in a
cellular context.
AsCpf1 extends the resolution of the methodology. The SpCas9
mutagenesis scanning approach may be limited by the availability
of NGG PAMs at or nearby the resistance hotspot of the
investigated drug. To mitigate this restraint, and to orthogonally
validate the strategy, we investigated whether the approach is
compatible with other endonucleases recognizing a different
PAM sequence such as the class 2 type V CRISPR-Cas AsCpf132.
We selected AsCpf1 crRNAs targeting TTTN motifs around
the same codons for XPO1, KIF11, and ERCC3 as described above
for SpCas9 (Fig. 5a and Supplementary Fig. 13a). These were
transfected along with AsCpf1 in HAP1 cells that were subse-
quently treated with the respective compounds. Colonies that
formed within a few days of treatment were drug resistant to the
speciﬁc treatment (Fig. 5b and Supplementary Fig. 13b) and
contained mutations at the known hotspots (Fig. 5c and
Supplementary Fig. 13c). We next designed a lentiviral tiling
crRNA library, similar to the SpCas9 library, spanning all possible
TTTN PAM sites in the coding sequence from 10 genes (1,100
crRNAs, Supplementary Data 8) and applied it to selinexor
(Fig. 5d). Colonies rapidly appeared and were resistant to seli-
nexor (Fig. 5e). One crRNA targeting codon C528 in XPO1, the
anchor point of selinexor, was highly enriched (71.9%) in the
resistant cell pool (Fig. 5f, g, and Supplementary Data 9).
Next-generation sequencing of the XPO1 locus revealed protein
variants that mainly consisted of a deletion of residues C528 and
E529 (Fig. 5h), identical to what we observed for the single
crRNA (Fig. 5c). Another crRNA targeting RPS3a was also
enriched, but could not be validated when transfected individu-
ally (data not shown). In addition, single-cell-derived clones
from the original resistant cell pool revealed that this RPS3a
crRNA always co-appeared with the XPO1C528 crRNA
(Supplementary Fig. 14a, b), suggesting that these cells were
transduced with two lentiviral particles and that decreasing the
multiplicity of infection (MOI) will reduce the false-positive rate.
To conclude, these results demonstrate that the CRISPR-based
mutagenesis scanning approach is compatible with AsCpf1
endonuclease, showing that the approach can be tailored to other
CRISPR-Cas endonucleases to increase the resolution of the
method.
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Discussion
One of the major challenges in drug discovery is the identiﬁcation
of the cellular target of a valuable bioactive small molecule.
Currently a wide range of target deconvolution technologies is
available2–4, but the gold standard for target conﬁrmation is the
identiﬁcation of mutations that confer drug resistance. Knowl-
edge of resistance mutations is not only used as a proof for target
engagement but can also provide functional insight into the
molecular biology of the target protein, and can be used to rescue
phenotypes from chemical genetic screens33.
Here, we show that genetic variation introduced by targeted
CRISPR-Cas-mediated NHEJ facilitates rapid selection of in-
frame drug resistance mutations in cancer cells. Because this
approach exploits the cellular error-prone DNA double
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strand break repair mechanism, it generates a wide diversity of
heterogeneous mutations. We demonstrate that this simple and
fast method can be applied as a genetic screening strategy using
large tiling libraries to identify the direct cellular target protein of
a small molecule. An important strength of this targeted muta-
genesis scanning method is that the sgRNA sequences directly
annotate the genomic sequence containing the drug resistance-
conferring mutations, avoiding the need for large whole-exome
sequencing and complex deconvolution endeavors to uncover the
relevant resistance mutations. In addition, a replicate screen
allowed for the detection of extremely low-frequency (0.02%)
sgRNA hits with high conﬁdence (Fig. 3d, e) facilitating the
identiﬁcation of unfrequent mutational hotspots conferring drug
resistance. Nevertheless, a single screen is sufﬁcient to detect the
important drug resistance-conferring sgRNAs with associated
mutations (Fig. 2). However, some false-positive sgRNAs were
detected from the single screen. This can be explained by co-
transduction of the resistance-conferring sgRNA with another
sgRNA in a small fraction of the cells, happening even at low
multiplicity of infection. Another source of noise can arise from
sgRNAs that were transduced in cells that already contain resis-
tance conferring mutations due to the heterogeneity and genetic
instability of the cancer cell line. These false-positive hits can be
eliminated by a replicate screen or by a simple validation
experiment of transfecting individual sgRNAs (Fig. 2e). Although,
in our screens, we did not observe activating mutations in other
proteins besides the target protein, these may obscure the iden-
tiﬁcation of the direct target itself. However, it remains to be seen
how often such mutations will occur and how they affect the
methodology.
Resistant cells elicited by this CRISPR-Cas mutagenesis
approach were commonly hemizygous for the resistance muta-
tion (Supplementary Fig. 1b); therefore, the approach allows for
the discovery of recessive mutations avoiding the need for haploid
cells. This is illustrated by triptolide resistance, for which a wild-
type allele is sufﬁcient for sensitivity14, in multiploid HCT 116
and HL-60 cells (Supplementary Fig. 6 and 7).
Recently, the targeting of cytidine deaminases with nuclease-
deﬁcient Cas9 has been shown to induce site-speciﬁc mutagenesis
without introducing a DSB to obtain drug resistance25, 34. The
experimental set up of the dCas9-cytidine deaminase fusion
approaches is different from the NHEJ-based mutagenesis
approach described here but the mutational spectra overlap
between both systems. However, the dCas9-cytidine deaminase
fusion approaches can logically not derive deletions or insertions.
We observed that in-frame deletions provide a major mechanism
for drug resistance, even in functionally important protein
domains. In addition, base-editing approaches are less probable to
recover recessive drug resistance mutations as this requires the
same mutation to be present in both alleles. Although the base
editing techniques can cover a mutational hotspot region of about
100 bases, they are limited to the introduction of an average of
1.32 base substitutions per read25. The NHEJ-based approach
described here covers a smaller hotspot region but generates
larger regions of genetic variation of up to 17 bases per read.
Using the CRISPRres approach, we revealed NAMPT as the
key cellular target of the clinical inhibitor KPT-9274 by showing
that mutations in NAMPT confer resistance to KPT-9274. Tumor
cells have been shown to be more dependent on the NAD+ sal-
vage pathway catalyzed by intracellular NAMPT35. Over-
expression of NAMPT has been observed in different cancer types
and has been implicated to confer resistance to classic che-
motherapeutics, whereas inhibition sensitizes cancer cells to
oxidative stress and DNA-damaging agents36. Thus, inhibition of
NAD+ biosynthesis facilitated by NAMPT shows potential as an
anticancer therapy. From this perspective, multiple efforts have
led to the discovery of NAMPT inhibitors37, 38. These inhibitors
induce delayed apoptosis or autophagy by gradual NAD+ or ATP
depletion, loss of plasma membrane potential, and possibly by
lowered activity of PARPs and SIRTs. Although NAMPT inhi-
bitors have entered clinical trials as a single agent (FK866/
APO866 and GMX1777/GMX1778), these failed to progress to
phase 2 due to on-target dose-limiting toxicity (mainly throm-
bocytopenia) and lack of clinical efﬁcacy39. This may partially be
explained by the still poorly understood aspects of NAMPT
biology in bigger biological systems, which might have led to the
selection of inappropriate indications or patient populations. In
addition, some of these inhibitors have relatively poor pharma-
cokinetics. KPT-9274 represents a new class of NAMPT inhibi-
tors and shows promising pharmacokinetics (Karyopharm
Therapeutics). Many studies have shown that KPT-9274 has
promising anticancer activity in vitro and in preclinical models,
and it has entered phase I clinical trials (ClinicalTrials.gov:
NCT02702492). These trials are designed to include an arm with
co-treatment of nicotinic acid and KPT-9274 to mitigate possible
side effects due to NAMPT inhibition. The existence of a sec-
ondary, NAPRT1-dependent, NAD+ salvage pathway, which
converts nicotinic acid to NAD+, may mitigate the observed dose-
limiting toxicity. Indeed, unlike many tumor types, normal tissue
cells express functional NAPRT1 and can generate NAD+ from
nicotinic acid. Therefore, this co-treatment may be one of the
keys to the success of KPT-9274 in the clinic.
Altogether our ﬁndings demonstrate that the localized genetic
variation generated by CRISPR-mediated NHEJ repair can be
exploited to screen essential genes for gain-of-function mutations.
We establish this mutagenesis scanning approach as a genetic
Fig. 5 Selection of resistance mutations generated using the AsCpf1 endonuclease. a An overview of AsCpf1 crRNAs targeting XPO1, KIF11, and ERCC3 at
their resistance hotspot residues. The AsCpf1 cleavage site, generating a four nucleotide overhang, is denoted by red arrowheads. b Cell viability of wild-
type and polyclonal mutagenized resistant cells in the presence of increasing concentration of drug. Values are shown relative to untreated controls. Data
points represent mean± s.d. obtained from two experiments performed in triplicate. c Amino-acid sequence variants determined by targeted amplicon-
sequencing analysis of the resistant cells with CrispRVariants. Only variants with a frequency ≥1% are shown. d An overview of the CRISPR-AsCpf1 tiling
crRNA library approach used for target identiﬁcation of selinexor. A lentiviral tilling library targeting 10 different genes was constructed and transduced in
cells stably expressing AsCpf1, which were ﬁrst selected with puromycin and subsequently treated with selinexor (2 µM). crRNAs present in resistant
colonies were identiﬁed by next-generation sequencing after which the genomic locus targeted by these crRNAs was sequenced to identify the resistance
conferring mutations in the target gene. e Cell viability in the presence of different concentrations of selinexor of wild-type and resistant cells obtained after
library transduction and selinexor treatment. Three experiments were performed in triplicate. Data points represent mean± s.d. f Representation of the
different crRNAs present in the cells before (after puromycin selection) and after treatment with selinexor as determined by EdgeR analysis of next-
generation sequencing data. A value of 1 was added to each read count to facilitate log transformation. Each dot represents a different crRNA. g crRNA hits
enriched over 100-fold in the selinexor-resistant cell pool after AsCpf1-mediated mutagenesis screen. Read counts were determined using EdgeR. h Amino-
acid variants detected in the XPO1 C528 locus of the resistant cells. Alterations were uncovered by CrispRVariants analysis of next-generation sequencing
data
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screen to identify the molecular target of chemical compounds
inhibiting essential proteins and the method is therefore com-
plementary to the loss-of-function screens. We envisage that this
genetic screen can either be applied on a list of candidate genes
identiﬁed after a ﬁrst round of target deconvolution by e.g.,
afﬁnity chemical proteomics, overexpression screens, or com-
parative studies such as CMap40, or it can be applied on a pre-
deﬁned shortlist of targets of interest. Indeed, it allows to rapidly
select from a primary screen those hit molecules that target a
protein or pathway of interest. Nevertheless, even when abso-
lutely no a priori knowledge on a potential target of a hit molecule
is available, the current format of the method allows coverage of
all essential genes41 with 20–25 tiling libraries for gene–drug
interaction discovery. Finally, we have illustrated the application
of this genetic screen for the identiﬁcation of drug–target inter-
actions using cellular toxicity as phenotypic selection, but it may
also be applicable to other phenotypic reporter assays.
Methods
Cell culture. HAP1 cells were obtained from Horizon Discovery. HCT 116, MIA
PaCa2, and K-562 cells were obtained from ATCC, HL-60 cells from Sigma
Aldrich, and OPM-2 from DSMZ. SpCas9 and AsCpf1 expressing cells were
generated in house. HAP1, HL-60, and K-562 cells were grown and passaged every
2–3 days in IMDM. HCT 116 cells were grown in McCoy’s 5A medium, MIA
PaCa2 cells were cultured in DMEM, and OPM-2 cells in RPMI 1640. All media
were supplemented with 10% fetal bovine serum and 20 µg/mL gentamicin. Cells
were incubated at 37 °C and 5% CO2 and were regularly checked for mycoplasma
contamination using the Venor GeM OneStep PCR kit (Minerva Biolabs).
Compounds. KPT-185, selinexor (KPT-330), KPT-9058, and KPT-9274 were
provided by Karyopharm Therapeutics (Newton, MA). Ispinesib, triptolide, bor-
tezomib, β-nicotinamide mononucleotide, and FK866 were obtained from Sell-
eckChem. All compounds were dissolved in DMSO, except for FK866, which was
dissolved in ethanol.
DNA constructs. The plasmid expressing humanized SpCas9 was obtained from
Labomics. The plasmid expressing humanized AsCpf1 was obtained from Addgene
(69982). Plasmids containing sgRNAs or crRNAs were cloned in house. The
pLCKO vector used for generation of the lentiviral library was obtained from
Addgene (73311). The plasmid encoding for the XPO1 reporter cargo, NLSSV40-
AcGFP-NESPKI, was cloned in house. Single-stranded DNA oligonucleotides for
use with HDR were obtained from Integrated DNA Technologies. See Supple-
mentary Data 10 for the sequences of the sgRNAs, crRNAs, and HDR templates.
Generation of stable SpCas9 and AsCpf1 HAP1 cell lines. Knock-in HAP1 cell
lines stably expressing SpCas9 or AsCpf1 were generated using the CRISPaint
principle42. Brieﬂy, cells were electroporated with the Neon Electroporation System
(Thermo Fisher Scientiﬁc) using 1450 V and 3 pulses of 10 ms in 10 µL Buffer R
(Neon Electroporation Kit). Cells were transfected with a plasmid encoding an
sgRNA targeting the C-terminus of SDHA (250 ng), a plasmid encoding SpCas9
and an sgRNA targeting the donor plasmid (250 ng), and a repair donor plasmid
containing a PAM and sgRNA targeting site and the sequence for P2A-mCherry-
T2A-SpCas9-P2A-HygroR or T2A-AsCpf1-P2A-HyrgoR (250 ng) to stably inte-
grate SpCas9 or AsCpf1 downstream of the SDHA housekeeping gene. K-562 cells
were transfected with a plasmid encoding a sgRNA targeting the AAVS1 safe
harbor locus, a plasmid encoding SpCas9 and a sgRNA targeting the donor plasmid
and a repair donor plasmid containing a PAM and sgRNA targeting site and the
sequence for CMV-mCherry-T2A-SpCas9-P2A-HygroR to stably integrate SpCas9
in the AAVS1 safe harbor locus. All cells were plated in a 6-well plate after
transfection and 2 days later, cells were selected with 300 μg/mL hygromycin B for
a period of 10 days and then checked for the expression of red ﬂuorescent
mCherry. SpCas9 or AsCpf1 endonuclease activity was assessed in the polyclonal
mixtures by indel detection using TIDE43 in XPO1 after sgRNA/crRNA transfec-
tion in the respective cell line.
Transfection. Cells were transfected with the Neon Electroporation System after
resuspension in Buffer R. DNA plasmids expressing the SpCas9 or AsCpf1
endonuclease and guiding RNA were added at a concentration of 37.5 ng/µL per
plasmid and electroporated at 1400–1475 V with 3 pulses of 10 ms. Two to three
days after transfection, cells were treated with the respective drug to select for
resistance over 7–14 days. Surviving cells were counted using trypan blue exclusion
staining or imaged with an IncuCyte© ZOOM (Essen Bioscience).
For HDR, a 123–134-bases-long ssDNA oligonucleotide (850 ng) was added to
the electroporation mixture in addition to the respective sgRNA and SpCas9
expressing plasmids. Two days after electroporation, cells were treated with the
respective drugs for 5 days before imaging with an IncuCyte© ZOOM (Essen
Bioscience). Following imaging, the HDR-template transfected cells were grown
under drug selection for an additional week before any further experiments were
performed.
Cell viability assays. Cell viability assays were performed by plating 3000 HAP1,
5000 HCT 116, K-562, or HL-60 cells in 96-well plates containing a dilution of the
test compound. Cells were incubated for 72 h at 37 °C and 5% CO2. Cell viability
was then assessed with the CellTiter 96® AQueous Non-Radioactive Cell Pro-
liferation Assay (Promega) and colorimetric signals were measured with a
Saﬁre2™ (TECAN). Assays were performed in triplicate and each experiment was
repeated at least once. Obtained values were adjusted with the background signal
and divided by the untreated control. Relative data values were then visualized and
analyzed using a log-based 4 parameter model (GraphPad Prism).
For single-guide drug resistance validation assays, 125.000 MIA PaCa2, OPM-2,
or HAP1/SpCas9+ and K-562/pCas9+ cells were transfected with plasmids
expressing individual sgRNAs, and if needed SpCas9, using the Neon
Electroporation system as described above and plated into 6-well plates. Cells were
treated 2–3 days after transfection with the respective compound for a period of
5–7 days, the medium was regularly refreshed, and dead cells were washed away
before imaging conﬂuency using a live cell analysis system (Essen Bioscience,
IncuCyte ZOOM®).
DNA extraction and sequencing. Genomic DNA was isolated from 1 million cells
with the QIAamp DNA mini kit using RNase A. For Sanger sequencing, the region
of interest was ampliﬁed by PCR with the CloneAmp HiFi PCR premix (Clontech).
The ampliﬁed DNA was then puriﬁed (QIAquick PCR puriﬁcation kit (Qiagen))
and sequenced (Macrogen). For targeted amplicon next-generation sequencing of
single-guide transfected cells, the region of interest (KIF11A133, XPO1C528,
ERCC3D54, ERCC3S162, NAMPTY18, NAMPTS240, or NAMPTG383) was ﬁrst ampli-
ﬁed over 24 cycles in 25 µL PCR reactions containing 50 ng genomic DNA with the
Phusion® High-Fidelity PCR Master Mix with HF Buffer (NEB) and with custom
primers containing adapter regions for Nextera indexes (IDT). Ampliﬁed DNA was
puriﬁed with the QiaQuick PCR puriﬁcation kit (Qiagen) and 1.5–2 µL of this
DNA was PCR ampliﬁed over 25 cycles with CloneAmp HiFi PCR Premix
(Clontech) using indexing primers containing P5 and P7 Illumina adapters in 25
µL reactions to index the samples. Indexed samples were puriﬁed using magnetic
Agencourt AMPure XP beads (Beckman Coulter) and eluted in TE buffer. Samples
were then diluted to 2–4 nM and pooled to form the initial library. This library was
then denatured and diluted according to the instructions for paired-end sequencing
on a MiSeq (Illumina) with a MiSeq V2–300 or 500 cycles kit (Illumina) and 10%
PhiX v3 (Illumina) spike-in. For a list of primers see Supplementary Data 10.
Analysis of next-generation sequencing data. FastQ ﬁles obtained after MiSeq
sequencing were demultiplexed with the MiSeq Reporter software (Illumina).
Demultiplexed and paired reads were trimmed, ﬁltered, and then aligned to the
reference amplicon in Geneious (v9, Biomatters). To obtain haplotypes present in
drug-resistant samples, bam ﬁles were analyzed with the CrispRVariants package
run in RStudio by deﬁning a 35–140 bp spanning region across the endonuclease
cut site, as deﬁned by pre-analysis of localized variants within Geneious. For this
purpose, the CrispRVariants “readtotarget” input was run with parameters
“upstream.snv” (15–70) and “downstream.snv” (15–70) on corresponding paired
end sequencing reads to allow for haplotype determination. Haplotype nucleotide
sequences were extracted with a small script. Nucleotide sequences were then
visualized and mapped to the reference in Geneious v9 (Biomatters) and amino-
acid variants were determined. For visualization of the spectra of single-nucleotide
variants, NGS reads were aligned to the reference gene. Nucleotide occurrence
frequencies were then determined in R on the aligned NGS reads using the
deepSNV Bioconductor package. Sequences containing sgRNA/crRNAs from the
pooled lentiviral screens were trimmed from adapter sequences. Individual sgRNA/
crRNA sequencing reads were then counted with EdgeR44 and the fold change of
enriched sgRNAs was calculated as follows and visualized using GraphPad Prism:
Log2
1þ ðRead Count perMillion ReadsÞafter drug treatment
1þ ðRead Count perMillion ReadsÞafter puromycin selection
 !
:
Cloning of the sgRNA and crRNA libraries. The 2,209 sgRNA sequences used in
the ispinesib-KIF11 pilot screen were obtained by selecting all N21GG sequences
available in the NCBI consensus coding sequences of the main isoforms of 9 genes
(KIF11, XPO1, ERCC3, PAK4, ABL1, TUBB, ACTB, RPS3a, and H2BFM2). Also
included were 100 control sgRNAs and all sgRNA sequences were appended 5′ and
3′ with small DNA sequences to facilitate PCR (total length 60 nt).
To obtain the AsCpf1 crRNA sequences, the coding sequence of the main
isoforms of 10 genes (KIF11, XPO1, ERCC3, PAK4, ABL1, TUBB, ACTB, RPS3a,
H2BFM2, and p53) were extracted from NCBI. For each intron–exon boundary, 25
nucleotides were added to the exonic sequences. From these sequences, all TTTN24
sequences were extracted and appended 5′ with the AsCpf1 direct repeat backbone
(TAATTTCTACTCTTGTAGA) and 30 scrambled control crRNAs were included.
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Sequences were then further appended 5′ and 3′ with small DNA sequences to
facilitate PCR (total length 79 nt).
The sgRNA sequences for the “FDA-target” and “non-FDA-target” libraries
were obtained with a custom script run in RStudio. In brief, target genes for the
libraries were roughly determined by the drug target list available for approved and
investigational antineoplastic agents on the Kyoto Encyclopedia of Genes and
Genomes (KEGG) database (retrieved July 2016) combined with a small literature
study. The target list was then ﬁltered from agents consisting of analogs of
nucleotide or metabolic products. The web-based Biomart (Ensemble) was used to
obtain the start and end coordinates of all CDS exons retrieved from the NCBI
refseq entries available for all isoforms of the predeﬁned target genes. Twenty base
pairs were added 5′ and 9 bp were added 3′ to each of the exonic start or end
coordinates on the forward and reverse strands, respectively, to include sgRNAs
located on exon–intron boundaries. These expanded and strand-speciﬁc
coordinates were used to search through the NCBI reference sequences to obtain all
N21GG sequences within these coordinates on both the forward and reverse
strands. Duplicate sgRNA sequences were removed on a gene-per-gene basis,
sgRNAs containing a TTTTT sequence were removed and sgRNAs were then
appended with additional sequences to facilitate PCR and the generation of
subpools. See Supplementary Data 1, 3, 4, and 8 for the gene target lists and the
individual sgRNA sequences.
All appended sgRNA and crRNA sequences were synthesized as pools by
Customarray Inc. (Bothell, WA) on a 12K (9/10 gene libraries) or 90K (“non-FDA-
target”/”FDA-target”) chip. The sgRNA/crRNA pools were ampliﬁed in 10 parallel
reactions (25 μL, 1 ng input) by PCR with the CloneAmp HiFi premix kit
(Clontech) and PCR products were puriﬁed with the QIAQuick Nucleotide
Removal kit (QiaGen). The puriﬁed PCR products were then subjected to
restriction digestion (six parallel reactions) with BfuAI (NEB) overnight at 50 °C.
After digestion, six ligation reactions containing 33 ng of digested sgRNA/crRNAs
and 500 ng of the BfuAI and NsiI predigested pLCKO vector were performed
overnight at 16 °C with T4 DNA ligase (NEB). The pooled mixture of ligated
pLCKO vectors was then puriﬁed with the QIAquick nucleotide removal kit
(Qiagen) and electroporated into Endura competent cells (Lucigen) with a Gene
Pulser system (Biorad) according to the manufacturer’s instructions. Transformed
cells were then plated in 15-cm-diameter petridishes containing prewarmed LB
agar with 100 µg/mL ampicilin and grown overnight at 32 °C. The following day
colonies were counted and a fold representation of 400 (“FDA” libraries A and B),
2700 (“non-FDA” libraries C and D), 30,000 (9 gene Cas9 library), or 90,000
(AsCpf1 library) was estimated. All colonies were pooled per library for plasmid
extraction with the PureLink® HiPure Plasmid Maxiprep (Invitrogen).
Lentiviral library. The pooled and puriﬁed pLCKO-U6-sgRNA/crRNA plasmid
libraries were provided to Applied Biological Materials Inc. (Richmond, BC,
Canada) to generate lentiviral particles coated with the VSV-G protein and con-
taining the desired genetic information for human expression of the sgRNA/
crRNAs. Viral stocks were titrated on wild-type HAP1 or K-562 cells to determine
the MOI.
Target identiﬁcation screens. HAP1 and K-562 cells stably expressing SpCas9 or
AsCpf1 were resuspended in supplemented IMDM containing 8 µg/mL polybrene
and transduced with lentiviral particles containing the desired sgRNA/crRNAs at
an MOI of 0.25 (coverage of 5000× per sgRNA for SpCas9) or 0.35 (coverage of
15,000× per crRNA for AsCpf1) by spinfection in 12-well plates containing 2 × 106
cells/well. For the bortezomib resistance screen, ~300 million cells were transduced
with sublibrary B, while for the KPT-9274 resistance screen ~400 million were
transduced with both sublibraries C and D. The next day cells were transferred to
T150 cell ﬂasks and were allowed to develop mutations for a period of 3–5 days
under puromycin selection. Then 4 million (ispinesib/selinexor) or 10 million
(KPT-9274/bortezomib) cells were harvested for DNA extraction and the
remaining cells were treated for a period of 2–3 weeks with 8 nM ispinesib, 30 nM
bortezomib, 300 nM (HAP1) or 500 nM (K-562) KPT-9274, or 2 µM selinexor. The
compound-containing medium was refreshed three times. After treatment, sur-
viving cells were harvested and the genomic DNA was extracted using the QiaGen
DNA mini kit and subjected to 5–10 parallel 100 µL PCR reactions (24 cycles, 2000
ng per reaction) with pLCKO primers carrying Nextera adapter sequences and
using the Phusion High-Fidelity PCR mastermix with HF buffer (NEB). Ampliﬁed
DNA was puriﬁed and pooled and a second PCR using the CloneAmp HiFi
Polymerase kit (Clontech) was performed over 24 cycles on 50 ng with Nextera
indexing primers (Illumina). Further processing for next-generation sequencing
analysis was performed as described above.
XPO1-mediated nuclear export phenotypic reporter assay. To study the XPO1-
mediated nuclear export, HAP1/SpCas9+ cells were transfected with a plasmid
encoding for the NLS-AcGFP-NES reporter construct and a plasmid pool encoding
4 sgRNAs targeting XPO1 for knockout. Cells were transfected with the Neon
Electroporation system as described above and plated in µ-slide 8-well glass bottom
plates (IBIDI). Two days after transfection, cells were treated with DMSO or 1 µM
selinexor for 3 h. After incubation, the AcGFP reporter construct was visualized in
live cells using a Leica SP5 confocal microscope employing a CX PL APO 63x (NA
1.2) objective. AcGFP was excited at 488 nm (argon laser) and emission was
detected at 492–560 nm.
Pull-down of XPO1 with KPT-9058. For pull-down of XPO1, parental HAP1 and
HDR-edited HAP1 cells were incubated with 2 µM of KPT-9058 for 3 h. Following
treatment, cells were washed in ice-cold PBS and pellets were lysed on ice in RIPA
buffer supplemented with 1× HALT protease inhibitors (Thermo Scientiﬁc).
Samples were cleared from debris by centrifugation at 18,000×g for 10 min at 4 °C.
Protein concentrations were measured with a colorimetric BSA protein assay
(Pierce). A fraction of the cell lysis mixture was taken for quantiﬁcation of β-
tubulin and XPO1 total protein. Remaining extracts were incubated with Dyna-
beads MyOne Streptavidin T1 (Life Technologies) to capture XPO1-bound KPT-
9058 by rotating overnight at 4 °C. The next morning, beads were collected with the
DnyaMag-2 (Life Technologies) and washed ﬁve times in modiﬁed RIPA buffer
(50 mM Tris-HCl pH 7.8, 150 mM NaCl, 1% NP-40 (IGEPAL CA-630), 0.1%
sodium deoxycholate, 1 mM EDTA). The captured proteins were eluted by boiling
the samples for 10 min in 0.5% SDS containing 1× sample buffer (Protein Simple).
Samples were separated by size (12–230 kDa) and visualized on a Wes system
(Protein Simple) with an anti-rabbit HRP conjugated antibody detecting the pri-
mary XPO1 (1/12,500, NB100–79,802) and β-Tubulin (1/3000, NB600–936) anti-
bodies. Protein signals were visualized and quantiﬁed with the Compass software,
v2.7.1 (Protein Simple).
Immunoﬂuorescence analysis of mitotic spindle formation. Parental HAP1 and
HDR-edited HAP1 cells were electroporated with a plasmid pool encoding for four
sgRNAs targeting KIF11 (for KIF11 knockout) or the AAVS1 locus (control) and
plated in 8-well chamber glass slides. The next morning, cells were treated with
DMSO or 50 nM ispinesib for 4 h. Cells were ﬁxed for 10 min at room temperature
using 4% PFA and permeabilized with PBS containing 0.1% Triton X-100 for 10
min. Afterwards, cells were washed with PBS and blocked with 10% normal goat
serum for 1 h at 37 °C. Subsequently, cells were stained with an α-tubulin primary
antibody (sc5286, Santa Cruz Biotech) dissolved in 10% normal goat serum for 1 h
at 37 °C. Following primary staining, cells were washed two times with PBS and
stained with a secondary antibody conjugated to Alexa Fluor 488 (1/500, A-11001,
Invitrogen) in the dark for 45 min at 37 °C. Nuclei were counterstained using the
NucBlue ﬁxed Cell stain (Life Technologies). Stained cells were imaged using a
Leica SP5 confocal microscope employing a CX PL APO 63× (NA 1.2) water
immersion objective. Alexa Fluor 488 and DAPI were detected using the excitation
line of 488 nm (argon laser) or the excitation line of 405 nm (pulsed diode laser),
respectively. Blue emission was detected between 410 and 480 nm, and green
emission was detected between 492 and 560 nm.
Determination of proteasome activity. Proteasome activity was determined using
the Proteasome GloTM Assay (Promega), and the assay was performed according to
the manufacturer’s instructions. Brieﬂy, site-speciﬁc luminogenic substrates were
added to determine the activity of the different catalytically active sites (Suc-LLVY-
aminoluciferin). Proteasome activity was determined at baseline and after a 2-h
incubation period (at 37 °C, 5% CO2) with 12.5 nM of bortezomib. The read-out
was performed on a Wallac Victor plate reader.
Determination of NAD+ levels. HAP-1 cells were plated in 96-well plates and
incubated overnight. The next day, a dilution series of KPT-9274 was added and
incubated overnight. NAD+ levels were determined the following day using
luminescence and the NAD+/NADH Glo Assay (Promega). NAD+ was obtained
from SelleckChem to generate a standard curve.
NAMPT crystalization. NAMPT was puriﬁed as previously described29. Brieﬂy,
full-length human NMPRTase was expressed with a C-terminal His tag in
Escherichia coli at 20 °C. A combination of nickel-agarose afﬁnity chromatography,
anion exchange and gel-ﬁltration chromatography was used to purify the pro-
tein. Crystals were grown for 5 days at 20 °C in hanging drops with a reservoir
solution of 0.2 M NaCl, 0.1 M Tris pH 8.5, and 22% PEG 3350. The drops were
composed of 1 μL NAMPT protein (10 mg/mL) and a 5-fold excess of KPT-9274 in
a 25 mM Tris, 150 mM NaCl, 5 mMM DTT pH 8.0 buffer and 1 μL of reservoir
solution. Crystals were shortly soaked in a cryoprotectant consisting of the reser-
voir solution with an additional 10% glycerol and ﬂash-frozen in liquid nitrogen.
Diffraction data were collected at the SSRF-BL17B beamline at 100 K using
0.95369 Å radiation using a Rayonix MX300 detector and processed with hkl3000.
PDB entry 4WQ6 was used as a starting point for molecular replacement and
structure reﬁnement utilizing CCP445, Phenix46, and Coot47 (see Supplementary
Fig. 12). The KPT-9247 structure was built into the difference map at the ligand
bind site, which shows a good agreement with the electron density (see Supple-
mentary Fig. 12). Following introduction of the mutations by modeling utilizing
MOE, the conformation of the residues within a 10-Å radius of the ligand was
energy optimized and the conformation changes at the ligand-binding site were
observed.
Data availability. The coordinates of the crystal are submitted to wwPDB as
5NSD. The used R scripts can be found in the Supplementary Software ﬁle.
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Sequencing data are available from the NCBI Sequencing Read Archive under the
accession code SRP126384 (Bioproject PRJNA419880). All other data are available
from the authors upon request.
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